机构名称：
¥ 1.0
注意：•目前正在研究接受免疫疗法的患者的疫苗接种安全性和功效2-5•避免在开始pembrolizumab之前，避免使用全身性皮质类固醇或免疫抑制剂，原因是由于潜在的干扰pembrolizumab的功效； corticosteroids or immunosuppressants may be used during treatment with pembrolizumab for the management of immune-mediated adverse reactions 6 • patients who may receive or have received allogeneic hematopoietic stem cell transplantation before or after retifanlimab treatment may be at increased risk of serious complications from their transplant, including graft- versus-host disease and sinusoidal obstruction syndrome 1 • solid organ transplant rejection has在接受其他PD-1抑制剂治疗的患者中报道了6
BC癌症方案摘要用于使用atezolizumab和bevacizumab
主要关键词
相关文件推荐
